Log In
Print this Print this

Oral TOP1288

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionOral formulation of a small molecule narrow-spectrum kinase inhibitor
Molecular Target p38 mitogen-activated protein kinase (p38 MAPK) (MAPK14) ; Src
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat ulcerative colitis (UC)
Regulatory Designation
PartnerTopiVert Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today